A new device on the market called UroLift, first approved by the US Food and Drug Administration and recently performed live at the UC San Diego School of Medicine, is the very first procedure of its type to relieve the symptoms of benign prostatic hypertrophy or BPH.
BPH is a condition of the male prostate. It involves benign enlargement of the prostate gland that occurs over time and results in symptoms of nocturia (using the restroom often during the night), dribbling urine, and difficulty starting a stream. BPH is extremely common, affecting approximately half of all men over the age of 60 and about 80 percent of men between the ages of 70-80.